BridgeBio raises up to $1.2B, a month after submitting cardio drug to FDA
2024-01-18
临床3期
BridgeBio has tapped investors for up to $1.25 billion as it prepares to commercialize its heart pill and get some breathing room to continue running multiple clinical trials across cardiorenal, oncology and other disease areas.
The financing haul arrives a month after BridgeBio
submitted
acoramidis for FDA approval and nearly four months after it inked a
$250 million private placement
.
Analysts and industry insiders
have been
waiting to see what kind of transaction the Palo Alto biotech would make after it announced its Phase III
cardio drug success
last year, which came after a
long odyssey
for the company and ended up being one of the industry’s
standout moments in 2023
.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。